Filter
1998
Filtered Results: 1998
Text search:
drug
regimens
Featured
Recommendations
205
New Publications
526
Language
Document type
No document type
1285
Guidelines
284
Studies & Reports
247
Manuals
62
Strategic & Response Plan
38
Fact sheets
35
Training Material
25
Situation Updates
7
Infographics
7
Resource Platforms
4
Brochures
2
Online Courses
2
Countries / Regions
India
120
South Africa
64
Kenya
52
Global
49
Ethiopia
48
Tanzania
47
Western and Central Europe
42
Uganda
37
Nigeria
36
Zambia
34
Nepal
31
Eastern Europe
31
Rwanda
28
Africa
26
Latin America and the Carribbean
25
Malawi
24
Ghana
22
Ukraine
21
Liberia
20
Philippines
18
Bangladesh
18
Namibia
18
Myanmar / Burma
18
Asia
17
Zimbabwe
16
Cambodia
14
Sierra Leone
13
Mozambique
12
South–East Asia Region
12
Russia
12
Lesotho
11
Indonesia
11
Botswana
10
Eswatini/ Swaziland
8
Colombia
7
Thailand
7
Cameroon
7
Senegal
7
Congo, Democratic Republic of
6
Brazil
6
Albania
5
Haiti
5
Georgia
5
Tajikistan
4
Syria
4
USA
4
Venezuela
4
West and Central Africa
4
East and Southern Africa
4
Argentina
4
Pakistan
4
Benin
3
China
3
Estonia
3
Germany
3
Western Pacific Region
3
Jamaica
3
Vietnam
3
Bhutan
3
South Sudan
3
Timor Leste/ East Timor
2
Burkina Faso
2
Afghanistan
2
Eastern Europe and Central Asia
2
Paraguay
2
North America
2
Sri Lanka
2
Sudan
2
Romania
2
Iraq
2
Somalia
2
North Macedonia
1
North Korea
1
El Salvador
1
Gambia
1
Chile
1
Iran
1
Fiji
1
Laos
1
Peru
1
Morocco
1
Guinea
1
Jordan
1
Saudi Arabia
1
Middle East and North Africa
1
Denmark
1
Tunisia
1
United Kingdom
1
Côte d’Ivoire / Ivory Coast
1
Bolivia
1
Lebanon
1
Papua New Guinea
1
Greece
1
Central African Republic
1
Solomon Islands
1
Authors & Publishers
Publication Years
Category
Countries
718
Clinical Guidelines
281
Public Health
87
Women & Child Health
70
Capacity Building
41
Key Resources
27
Pharmacy & Technologies
18
Toolboxes
TB
377
HIV
352
NTDs
91
AMR
78
Pharmacy
60
Mental Health
47
COVID-19
45
NCDs
45
Ebola & Marburg
29
Refugee
23
Caregiver
23
Conflict
16
Rapid Response
15
Polio
11
Disability
9
Health Financing Toolbox
7
Specific Hazards
4
Natural Hazards
4
Planetary Health
4
Malaria
4
Global Health Education
4
Cholera
3
Social Ethics
3
Zika
1
Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis
recommended
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an...
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown...
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ...
This e-course will guide you through the essentials of latest existing WHO guidelines and policy recommendations on drug-resistant TB. You will also learn more about the rationale behind the WHO recommendations for the management of DR-TB, implementation considerations for different regimens for eli...
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Ra...
This study aimed to understand the patterns of HIV drug resistance in pregnant women in Mozambique. This might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care.
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens.
Results are used to inform A...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps...
Meeting Report 27-29 October 2020
The overall goal of the meeting was to discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB, with a view to revising this definition. The pre-existing definition of XDR-TB w...
Specific measures are being taken within the National Tuberculosis Control Programme (NTP) to address the MDR TB problem through appropriate management of patients and strategies to prevent the propagation and dissemination of MDR TB.
The term "Programmatic Management of Drug Resistant TB" (PMD...
The term "Programmatic Management of Drug Resistant TB" (PMD...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and ...
